Why the study?
Do heparin and its fractions induce platelet aggregation in human platelets?
Do heparin and its fractions induce platelet aggregation in human platelets?
Heparin induces concentration-dependent platelet aggregation partially through thromboxane production, an effect that is not always completely neutralized by protamine.
Answers are grounded in this paper and cite their sources.
Does not support changes in clinical heparin use; leaves open translation of thromboxane-mediated aggregation to human platelets in vivo.
We have shown that heparin and heparin fractions cause in vitro platelet aggregation in a large portion of a normal population. Furthermore, this aggregation occurs in a concentration-dependent manner and is not related to the anti-Xa activity of heparin or its fractions. In addition, it appears that at least part of the mechanism by which heparin induces aggregation is through the production of thromboxane. However, this is not the sole mechanism, since approximately 20% aggregation still occurs when thromboxane production is totally inhibited or the thromboxane receptor is completely blocked. Furthermore, although protamine (at the concentrations used) completely neutralizes the anticoagulant activity of heparin, it does not always completely inhibit the platelet aggregating activity of heparin. Finally, we have shown that heparin alone promotes thromboxane production and PF4 release in a whole blood system. Additional studies are needed to characterize further the mechanisms of heparin-induced platelet aggregation.
No takes yet. Share an insight, caveat, or question.
Brace et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: